

For Public Release NZX Limited Wellington

14 September 2023

Cannasouth exports first Cannabis-based Active Pharmaceutical Ingredient

Cannasouth Limited (NZX:CBD) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand's medicinal cannabis industry.

This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.

This signals the next growth phase for Cannasouth and the medicinal cannabis industry.

-ENDS-

For further information visit <u>www.cannasouth.co.nz</u> or contact:

Mark Lucas

CEO / Executive Director Email: <u>mark.lucas@cannasouth.co.nz</u> Mobile: 021 484 649 **Colin Foster** CFO / Company Secretary Email: <u>colin.foster@cannasouth.co.nz</u> Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <u>https://www.cannasouth.co.nz/about/media/</u>